Table 1. Cytotoxicity of the Investigated Platinum(IV) Complexes in Comparison with the Clinically Applied Platinum(II) Drugs in the CH1 and SW480 Human Cancer Cell Lines.

	IC50 (μM)a			IC50 (μM)a
compd	CH1	SW480	compd	CH1	SW480
1	19 ± 1	136 ± 16	30	24 ± 5	>500
2	0.62 ± 0.32	3.8 ± 1.0	31	8.6 ± 1.7	350 ± 39
3	28 ± 2	183 ± 28	32	11 ± 6	181 ± 44
4	12 ± 4	48 ± 4	33	62 ± 26	>500
5	1.9 ± 0.2	24 ± 4	34	44 ± 8	>500
6	5.5 ± 2.2	95 ± 5	35	15 ± 5	>500
7	0.68 ± 0.20	16 ± 1	36	28 ± 2	>500
8	0.34 ± 0.11	4.1 ± 0.5	37	31 ± 13	>500
9	0.068 ± 0.024	0.63 ± 0.20	38	114 ± 23	>500
10	0.018 ± 0.007	0.22 ± 0.08	39	33 ± 13	>500
11	24 ± 3	142 ± 23	40	7.7 ± 1.4	>250
12	2.3 ± 1.1	31 ± 15	41	89 ± 7	>500
13	1.9 ± 0.2	19 ± 9	42	128 ± 48	>500
14	32 ± 19	160 ± 10	43	23 ± 9	>500
15	1.1 ± 0.2	3.5 ± 0.1	44	49 ± 13	>500
16	21 ± 8	90 ± 21	45	125 ± 35	>500
17	22 ± 12	43 ± 22	46	22 ± 8	>500
18	7.8 ± 1.0	21 ± 5	47	33 ± 4	>500
19	0.17 ± 0.05	2.9 ± 1.0	48	21 ± 6	>500
20	0.055 ± 0.006	0.96 ± 0.4	49	1.9 ± 0.3	100 ± 6
21	5.6 ± 1.6	40 ± 12	50	2.1 ± 0.3	161 ± 33
22	0.16 ± 0.05	1.0 ± 0.3	51	55 ± 28	44 ± 9
23	0.061 ± 0.015	0.30 ± 0.05	52	19 ± 5	14 ± 3
24	0.014 ± 0.002	0.11 ± 0.01	53	11 ± 2	12 ± 5
25	0.0094 ± 0.0012	0.39 ± 0.07	cisplatin	0.16 ± 0.03	3.50 ± 0.29
26	0.75 ± 0.10	6.1 ± 0.6	carboplatin	1.36 ± 0.40	85 ± 28
27	171 ± 1	>500	oxaliplatinb	0.33 ± 0.09	0.30 ± 0.08
28	32 ± 10	>500	nedaplatin	0.14 ± 0.05	6.3 ± 1.3
29	28 ± 4	>500

^aThe reported 50% inhibitory concentrations are the means ± standard deviations obtained from three independent experiments.

^bData taken from ref (24).